Seeking Alpha

Professorredbag

Professorredbag
Send Message
View as an RSS Feed
View Professorredbag's Comments BY TICKER:
Latest  |  Highest rated
  • Provectus' Latest Developments Spark Investor Interest -- CFO/COO Culpepper Explains Why [View article]
    I actually expected a longer wait (more typical of small biopharms) for significant news to come once the FDA entanglements were sorted though pre/post BTD application and decision. I agree with Peter that the result has been, ultimately, positive for Provectus (NYSE:PVCT) for the reason he states.

    What is often not said is as important as what is. It seems clear, IMO, the FDA was caught in the middle of bureaucratic guideline shifts with the new BTD and didn't communicate these to the company until it was too late. However, with a drug as important as PV-10, it is especially important not to spend time whining about what should have been and take the best of what is and move forward which is what they are doing.

    This drug has had major skeptics for years (there are still draggers) but in the scientific/medical community there has been and continues to be a major shift in acceptance of the credibility/viability of the drug at home and abroad and the blockbuster potential it has medically and financially. The MOU with Sinopharm is but one instance of this acceptance.

    Patience is the single most important attribute for a long investor in any stock, once a level of due diligence triggers the investment. If the buyout/partnership comes tomorrow, in six months or a year's time, those of us who have recognized the potential for months if not years and invested at current levels or below will be very well rewarded.

    I have a feeling the positive and concrete news will continue to come until that reward materializes from the hard work the company management has been and continues to do. New investors will be wise, IMO, to get on board as soon as possible if they want to make money and/or support a company that is going to make an historical mark on the road to curing many types of cancer.
    Aug 22, 2014. 06:40 PM | 9 Likes Like |Link to Comment
  • The Product Development Story Of Provectus Biopharmaceuticals [View article]
    Re: (Dilution and Exec Comp issues) New financial analysis (comforting) on Trust Intelligence site. http://bit.ly/1qUibHA
    Aug 4, 2014. 11:32 AM | Likes Like |Link to Comment
  • The Product Development Story Of Provectus Biopharmaceuticals [View article]
    There are no promises in the article, just facts. Good for you to have taken some profit? Why did you invest in the first place? Ah, therein perhaps, lies the rub.
    Jul 28, 2014. 03:00 PM | 4 Likes Like |Link to Comment
  • The Product Development Story Of Provectus Biopharmaceuticals [View article]
    M Plaut. Thank you for this excellent research. People who can actually read and understand the words will benefit.
    Jul 28, 2014. 02:22 PM | 5 Likes Like |Link to Comment
  • The Product Development Story Of Provectus Biopharmaceuticals [View article]
    Dear Richard, Please do your Due Diligence and look for a report on the very issue of finance on the Trust Intelligence site later this week. http://bit.ly/1o6TK1A

    And for a thorough explanation of what the company was doing from end of P2 and the good and surprising data that resulted as well as insightful articles on the finance situation see the Provectus Blog http://bit.ly/1prAgYv

    Your comments about the FDA will also be addressed on these and other legitimate sites.

    The major institutional investors in this stock will not allow it to be delisted. Tune in to the August 7th conference call if you want the current news.
    Jul 28, 2014. 02:20 PM | 7 Likes Like |Link to Comment
  • Provectus Is Still Overvalued: Accounting For Risk And Dilution Takes The Value Of This Company Below $0.20 Per Share [View article]
    Thank you for a well researched, rational response. In line with other rational 'defenders' of this novel drug, critically important data and facts 'from the horses mouth' are presented. There is no need to debase ourselves further by stooping to the emotional and greed driven level of lies, censored information and innuendo the majority of detractors here and elsewhere pen. Writing anything of value, whether long or short, on a stock needs to be based on verifiable facts and without malice. Peace!
    May 29, 2014. 02:27 PM | 2 Likes Like |Link to Comment
  • Provectus Is Still Overvalued: Accounting For Risk And Dilution Takes The Value Of This Company Below $0.20 Per Share [View article]
    Spurious idiocy.
    May 29, 2014. 10:12 AM | 3 Likes Like |Link to Comment
  • Provectus Forges Ahead After FDA Setback [View article]
    Finally, an honest fact-filled article. Kudos Alan and PVCT personnel for answers to the point. Old paradigms crumble slowly and new ones rise at the same pace.
    May 27, 2014. 10:26 AM | 15 Likes Like |Link to Comment
  • PV-10 application rejected by FDA [View news story]
    The company has. Contact them. http://www.pvct.com
    May 27, 2014. 08:57 AM | Likes Like |Link to Comment
  • Even If Provectus Successfully Markets PV-10 For Melanoma, It's Worth A Fraction Of The Current Stock Price [View article]
    More selective, incomplete, biased drivel. So fraught with gaping holes I won't even bother to start.
    May 27, 2014. 07:04 AM | 7 Likes Like |Link to Comment
  • PV-10 application rejected by FDA [View news story]
    "curiously seeming to boast" - such a subjective interpretation is very much out of place...unfortunately becoming more common and therefore reducing the credibility of the information 'editors' sanction for publication on this site. Isn't one of the axioms of good investing and investment advise to leave emotions at the door? Criticizing management based on facts, not innuendo, makes it fair game.
    May 26, 2014. 10:11 AM | 1 Like Like |Link to Comment
  • PV-10 application rejected by FDA [View news story]
    It is better than any other drug...a 64% CR (complete response) rate is unprecedented. It is hardly irrelevant that the drug works. It works so well that resected tumors after treatment had NO determinable remnants of the cancer. The safety data was not sufficient for the FDA. Their guidelines could somehow not reconcile eliminating the tumor with relief of secondary end points of pain, bleeding, infection. These endpoints can be and will be easily proven. It just sets back the timeline for melanoma but liver and breast trials are on track. I don't know about you but I think curing any cancer will be a major milestone and a huge winner for investors...and patients.
    May 26, 2014. 09:55 AM | 2 Likes Like |Link to Comment
  • PV-10 application rejected by FDA [View news story]
    At this point, understanding the issue from both sides, a short bridge study may be undertaken unless they can reassemble some data to satisfy the need for the bleeding, pain, and infection end points which were the cause for the rejection of this BTD. The 64% complete response rate is unquestionable. A full blown study is not necessary though the company may choose to do this to drive the safety and efficacy of the drug beyond any question. Just how many lives may be lost in the meantime needs to be considered.
    May 25, 2014. 10:42 AM | 1 Like Like |Link to Comment
  • PV-10 application rejected by FDA [View news story]
    Please do your research. Start by listening to the conference call of the 23rd which adequately answers your question.
    May 25, 2014. 10:35 AM | 1 Like Like |Link to Comment
  • PV-10 application rejected by FDA [View news story]
    If you listened to the conference call, you would know the answer to your 1st question. There is no potential, the drug's efficacy has already been proven and is beyond question, even by the FDA. The only 'potential' is in how much money they will get in a buy-out or taking the drug to market themselves. Big pharma has already expressed its interest but the company will not (rightfully) undersell the potential it has.
    May 25, 2014. 10:32 AM | 1 Like Like |Link to Comment
COMMENTS STATS
36 Comments
101 Likes